Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-07, Vol.133, p.38-44
• Main Authors: Sakin, Abdullah, Sahin, Suleyman, Yasar, Nurgul, Demir, Cumhur, Arici, Serdar, Geredeli, Caglayan, Cihan, Sener
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Allogeneic blood transfusion; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Blood Transfusion - methods; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - therapy; Chemotherapy; Female; Humans; Lung cancer; Lung Neoplasms - diagnosis; Lung Neoplasms - mortality; Lung Neoplasms - therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Non-small cell lung adenocarcinoma; Prognosis; Retrospective Studies; Survival; Survival Analysis; Transplantation, Homologous; Young Adult
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2019.05.007

•Blood Transfusion may cause various immune system dysfunctions, leading to immunosuppression.•The advers effect of blood transfusions in cancer patients has been investigated in various cancer types.•The knowledge on this issue has been under debate in lung cancer.•Blood trasfusion is associated with earlier progression and shorter survival in Lung adenocancer. To investigate the prognostic effects of Allogeneic Blood Transfusion (ABT) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) receiving Chemotherapy (CT) in the first-line treatment, comparing untransfused patients to those receiving blood transfusion during treatment period or before treatment period. This was a retrospective study of 433 patients with metastatic NSCLC receiving CT in the first-line treatment. Patients were categorized into 3 groups according to the transfusion strategy as follows; group-U(Untransfused patients, n = 303), group-B(patients receiving transfusion Before treatment period, n = 43), and group-D(patients receiving transfusion During treatment period, n = 87). There were 433 patients in the analysis, consisting of 388 (89.6%) males, with a median age of 60 years(range, 21–92). The median Overall Survival(mOS) according to the ABT was 14 months for group-U, 9 months for group-B, and 7 months for group-D (p